Durable complete responses with CAR-NK + Rituximab in patients who failed current standards of care in Waldenstrom’s Non-Hodgkins lymphoma (NHL). Long-term evaluable patients demonstrate ongoing ...
Bicistronic CD19/CD22-directed CAR-T cell therapy achieved high remission rates and durable responses in pediatric B-ALL patients. One-year EFS and OS rates were 75.5% and 93.5%, respectively, with ...
MISSISSAUGA, Ontario, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Next Hydrogen Solutions Inc. (NXH:CA) (the “Company” or “Next Hydrogen“) (TSXV:NXH, OTC:NXHSF), a designer and manufacturer of electrolyzers, is ...
NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (INKT) cell therapies, today announced the publication of another landmark case in Nature’s Oncogene describing a complete and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results